Rizatriptan Benzoate Tablet
Product Images NDC 57237-088

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 57237-088). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
Figure 1 illustrates the estimated probability of achieving an initial headache response by 2 hours in four pooled studies using rizatriptan benzoate 5mg, rizatriptan benzoate 10mg or a placebo. The graph shows a Kaplan-Meier plot of the probability over time of obtaining headache response (no or mild pain) following treatment with rizatriptan benzoate or placebo. The data is based on pooled data from 4 placebo-controlled, outpatient trials providing evidence of efficacy (Studies 1, 2, 3, and 4). Patients taking additional treatment or not achieving headache response prior to 2 hours were censored at 2 hours. The percentages shown in the graph indicate the estimated probability of response at each time-point evaluated.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
This is a figure that shows the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over 24 hours following the initial dose of study treatment in pooled studies 1, 2, 3, and 4. The plot is a Kaplan-Meier plot, and it includes both patients who had headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)
The text describes a Figure 5 which shows the percentage of patients with no headache pain two hours after taking Rizatriptan Benzoate Orally Disintegrating Tablets and a placebo. The graph shows the observed percentage of patients reporting no headache pain by time (in hours) after the Stage 2 dose.*
FDA Label Image

Package Label-principal Display Panel (5 mg 18 Tablets (3 Blister Cards of 6 Tablets each))

Package Label-principal Display Panel (5 mg 18 Tablets (3 Blister Cards of 6 Tablets each))
This is a description of Rizatriptan Benzoate Tablets, USP, from the Ove Printing Zone. The medication comes in a package containing 12 tablets, with four blister cards of three tablets each. The active ingredient in each tablet is 126 grams of Rizatriptan Benzoate, and the recommended adult dosage is not provided. The medication should be stored at controlled room temperature, preferably between 20° and 25°C. The rest of the text contains irrelevant or unreadable characters.*
FDA Label Image

Package Label-principal Display Panel -10 mg 18 Tablets (3 Blister Cards Of 6 Tablets Each) (Rizatriptan Fig5)

Package Label-principal Display Panel -10 mg 18 Tablets (3 Blister Cards Of 6 Tablets Each) (Rizatriptan Fig5)
This is a description of a medication called Rizatriptan Benzoate Tablets. It is a drug used for adults and is typically stored at a temperature between 20 to 25 degrees Celsius. The package includes 12 tablets distributed on four blister cards, with each card containing three tablets. The usual adult dosage is not available.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.